USCOM Ltd
UCM
Company Profile
Business description
USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. The company generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology.
Contact
Level 8, 66 Clarence Street
Suite 2
SydneyNSW2000
AUST: +61 292474144
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
11
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.20 | 61.30 | -0.67% |
| CAC 40 | 7,853.59 | 1.02 | -0.01% |
| DAX 40 | 23,639.41 | 35.12 | -0.15% |
| Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
| FTSE 100 | 9,216.67 | 11.44 | -0.12% |
| HKSE | 26,545.10 | 106.59 | 0.40% |
| NASDAQ | 22,631.48 | 160.75 | 0.72% |
| Nikkei 225 | 45,045.81 | 143.54 | 0.32% |
| NZX 50 Index | 13,231.66 | 3.23 | -0.02% |
| S&P 500 | 6,664.36 | 32.40 | 0.49% |
| S&P/ASX 200 | 8,773.50 | 75.00 | -0.85% |
| SSE Composite Index | 3,820.09 | 11.57 | -0.30% |